Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome

References

• World Health Organization. Hepatitis C fact sheet No164 [Internet]. [Updated 2013 Jul; Cited 2013 Nov 13]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
   Google Scholar
• World Health Organization. Hepatitis C [Internet]. 2002. [Cited 2013 Nov 13]. Available from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index2.html.
   Google Scholar
• Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962 - 73; http://dx.doi.org/10.1002/hep.20819; PMID: 16149085
   PubMed Web of Science ®Google Scholar
• Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, Esteban R, Abdo AA, Harrison SA, Ibrahim N, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54:1250 - 62; http://dx.doi.org/10.1016/j.jhep.2010.11.016; PMID: 21316497
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Hepatitis C Information for Health Professionals [Internet]. 2011. [Cited 2013 Nov 13]. Available from: http://www.cdc.gov/hepatitis/HCV/index.htm
   Google Scholar
• Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5:453 - 63; http://dx.doi.org/10.1038/nrmicro1645; PMID: 17487147
   PubMed Web of Science ®Google Scholar
• Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008; 128:133 - 47; http://dx.doi.org/10.1016/j.clim.2008.03.525; PMID: 18514579
   PubMed Web of Science ®Google Scholar
• Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119:1745 - 54; http://dx.doi.org/10.1172/JCI39133; PMID: 19587449
   PubMed Web of Science ®Google Scholar
• Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 2010; 285:22741 - 7; http://dx.doi.org/10.1074/jbc.R109.099556; PMID: 20457596
   PubMed Web of Science ®Google Scholar
• Zeisel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 2008; 48:299 - 307; http://dx.doi.org/10.1002/hep.22307; PMID: 18508291
   PubMed Web of Science ®Google Scholar
• Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 2011; 10:659 - 72; http://dx.doi.org/10.1586/erv.11.55; PMID: 21604986
   PubMed Web of Science ®Google Scholar
• Yu CI, Chiang BL. A new insight into hepatitis C vaccine development. J Biomed Biotechnol 2010; 2010:548280; http://dx.doi.org/10.1155/2010/548280; PMID: 20625493
   PubMed Web of Science ®Google Scholar
• Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010; 139:965 - 74; http://dx.doi.org/10.1053/j.gastro.2010.05.077; PMID: 20621699
   PubMed Web of Science ®Google Scholar
• Kim Y, Vaughan K, Greenbaum J, Peters B, Law M, Sette A. A meta-analysis of the existing knowledge of immunoreactivity against hepatitis C virus (HCV). PLoS One 2012; 7:e38028; http://dx.doi.org/10.1371/journal.pone.0038028; PMID: 22675428
   PubMedGoogle Scholar
• Yahia M. Global health: a uniquely Egyptian epidemic. Nature 2011; 474:S12 - 3; http://dx.doi.org/10.1038/474S12a; PMID: 21666728
   PubMedGoogle Scholar
• De Groot AS. Epitope-based immunome-derived vaccines: A strategy for improved design and safety. Springer, NY; 2009.
   Google Scholar
• iCubed: Institute for Immunology and Informatics. iVAX Tool Kit [Internet]. 2012. [Cited 2013 Nov 13]. Available from: http://www.immunome.org/ivax/ivax-tool-kit/.
   Google Scholar
• Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, Fleri W, Kronenberg M, Kubo R, Lund O, et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 2005; 3:e91; http://dx.doi.org/10.1371/journal.pbio.0030091; PMID: 15760272
   PubMed Web of Science ®Google Scholar
• Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50:201 - 12; http://dx.doi.org/10.1007/s002510050594; PMID: 10602880
   PubMed Web of Science ®Google Scholar
• Petrovic D, Dempsey E, Doherty DG, Kelleher D, Long A. Hepatitis C virus--T-cell responses and viral escape mutations. Eur J Immunol 2012; 42:17 - 26; http://dx.doi.org/10.1002/eji.201141593; PMID: 22125159
   PubMed Web of Science ®Google Scholar
• Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, VerBerkmoes NC, Sztein MB, Losikoff PT, Martin WD, et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother 2013; 9:1577 - 86; http://dx.doi.org/10.4161/hv.24615; PMID: 23584251
   PubMed Web of Science ®Google Scholar
• Neumann-Haefelin C, Killinger T, Timm J, Southwood S, McKinney D, Blum HE, Thimme R. Absence of viral escape within a frequently recognized HLA-A26-restricted CD8+ T-cell epitope targeting the functionally constrained hepatitis C virus NS5A/5B cleavage site. J Gen Virol 2007; 88:1986 - 91; http://dx.doi.org/10.1099/vir.0.82826-0; PMID: 17554032
   PubMed Web of Science ®Google Scholar
• Neumann-Haefelin C, Timm J, Spangenberg HC, Wischniowski N, Nazarova N, Kersting N, Roggendorf M, Allen TM, Blum HE, Thimme R. Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology 2008; 47:1824 - 36; http://dx.doi.org/10.1002/hep.22242; PMID: 18454507
   PubMed Web of Science ®Google Scholar
• Wentworth PA, Sette A, Celis E, Sidney J, Southwood S, Crimi C, Stitely S, Keogh E, Wong NC, Livingston B, et al. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int Immunol 1996; 8:651 - 9; http://dx.doi.org/10.1093/intimm/8.5.651; PMID: 8671652
   PubMed Web of Science ®Google Scholar
• Mashiba T, Udaka K, Hirachi Y, Hiasa Y, Miyakawa T, Satta Y, Osoda T, Kataoka S, Kohara M, Onji M. Identification of CTL epitopes in hepatitis C virus by a genome-wide computational scanning and a rational design of peptide vaccine. Immunogenetics 2007; 59:197 - 209; http://dx.doi.org/10.1007/s00251-006-0185-3; PMID: 17225159
   PubMed Web of Science ®Google Scholar
• Nakamoto Y, Kaneko S, Takizawa H, Kikumoto Y, Takano M, Himeda Y, Kobayashi K. Analysis of the CD8-positive T cell response in Japanese patients with chronic hepatitis C using HLA-A*2402 peptide tetramers. J Med Virol 2003; 70:51 - 61; http://dx.doi.org/10.1002/jmv.10349; PMID: 12629644
   PubMed Web of Science ®Google Scholar
• Kaji K, Nakamoto Y, Kaneko S. Analysis of hepatitis C virus-specific CD8+ T-cells with HLA-A*24 tetramers during phlebotomy and interferon therapy for chronic hepatitis C. Oncol Rep 2007; 18:993 - 8; PMID: 17786365
   PubMed Web of Science ®Google Scholar
• Gruener NH, Jung MC, Ulsenheimer A, Gerlach JT, Zachoval R, Diepolder HM, Baretton G, Schauer R, Pape GR, Schirren CA. Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation. Liver Transpl 2004; 10:1487 - 96; http://dx.doi.org/10.1002/lt.20300; PMID: 15558593
   PubMed Web of Science ®Google Scholar
• Christie JM, Chapel H, Chapman RW, Rosenberg WM. Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Hepatology 1999; 30:1037 - 44; http://dx.doi.org/10.1002/hep.510300403; PMID: 10498657
   PubMed Web of Science ®Google Scholar
• Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004; 127:924 - 36; http://dx.doi.org/10.1053/j.gastro.2004.06.015; PMID: 15362047
   PubMed Web of Science ®Google Scholar
• Cucchiarini M, Kammer AR, Grabscheid B, Diepolder HM, Gerlach TJ, Grüner N, Santantonio T, Reichen J, Pape GR, Cerny A. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 2000; 203:111 - 23; http://dx.doi.org/10.1006/cimm.2000.1683; PMID: 11006009
   PubMed Web of Science ®Google Scholar
• Grüner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, Hoffmann R, Zachoval R, Santantonio T, Cucchiarini M, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181:1528 - 36; http://dx.doi.org/10.1086/315450; PMID: 10823750
   PubMed Web of Science ®Google Scholar
• Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, Reiser M, Kim AY, Lucas M, Klenerman P, et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002; 76:6104 - 13; http://dx.doi.org/10.1128/JVI.76.12.6104-6113.2002; PMID: 12021343
   PubMed Web of Science ®Google Scholar
• Grey HM, Ruppert J, Vitiello A, Sidney J, Kast WM, Kubo RT, Sette A. Class I MHC-peptide interactions: structural requirements and functional implications. Cancer Surv 1995; 22:37 - 49; PMID: 7536628
   PubMedGoogle Scholar
• Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74:929 - 37; http://dx.doi.org/10.1016/0092-8674(93)90472-3; PMID: 8104103
   PubMed Web of Science ®Google Scholar
• Bertoni R, Sette A, Sidney J, Guidotti LG, Shapiro M, Purcell R, Chisari FV. Human class I supertypes and CTL repertoires extend to chimpanzees. J Immunol 1998; 161:4447 - 55; PMID: 9780224
   PubMed Web of Science ®Google Scholar
• Alexander J, Del Guercio MF, Fikes JD, Chesnut RW, Chisari FV, Chang KM, Appella E, Sette A. Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Hum Immunol 1998; 59:776 - 82; http://dx.doi.org/10.1016/S0198-8859(98)00080-9; PMID: 9831133
   PubMed Web of Science ®Google Scholar
• Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, Chircu ML, Sidney J, Southwood S, Abrignani S, et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999; 162:6681 - 9; PMID: 10352286
   PubMed Web of Science ®Google Scholar
• Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ, Sette A. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 2001; 62:1200 - 16; http://dx.doi.org/10.1016/S0198-8859(01)00319-6; PMID: 11704282
   PubMed Web of Science ®Google Scholar
• Himoudi N, Abraham JD, Fournillier A, Lone YC, Joubert A, Op De Beeck A, Freida D, Lemonnier F, Kieny MP, Inchauspé G. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol 2002; 76:12735 - 46; http://dx.doi.org/10.1128/JVI.76.24.12735-12746.2002; PMID: 12438599
   PubMed Web of Science ®Google Scholar
• Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A, Celis E, Ching WM, Grakoui A, Rice CM, Kurokohchi K, et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995; 69:2462 - 70; PMID: 7884894
   PubMed Web of Science ®Google Scholar
• Ohno S, Moriya O, Yoshimoto T, Hayashi H, Akatsuka T, Matsui M. Immunogenic variation between multiple HLA-A*0201-restricted, Hepatitis C Virus-derived epitopes for cytotoxic T lymphocytes. Viral Immunol 2006; 19:458 - 67; http://dx.doi.org/10.1089/vim.2006.19.458; PMID: 16987064
   PubMed Web of Science ®Google Scholar
• Ishizuka J, Grebe K, Shenderov E, Peters B, Chen Q, Peng Y, Wang L, Dong T, Pasquetto V, Oseroff C, et al. Quantitating T cell cross-reactivity for unrelated peptide antigens. J Immunol 2009; 183:4337 - 45; http://dx.doi.org/10.4049/jimmunol.0901607; PMID: 19734234
   PubMed Web of Science ®Google Scholar
• Anthony DD, Valdez H, Post AB, Carlson NL, Heeger PS, Lehmann PV. Comprehensive determinant mapping of the hepatitis C-specific CD8 cell repertoire reveals unpredicted immune hierarchy. Clin Immunol 2002; 103:264 - 76; http://dx.doi.org/10.1006/clim.2001.5193; PMID: 12173301
   PubMed Web of Science ®Google Scholar
• Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, Sims S, Dempsey E, Freitas E, Lea S, et al. Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. Gut 2011; 60:1563 - 71; http://dx.doi.org/10.1136/gut.2010.228403; PMID: 21551190
   PubMed Web of Science ®Google Scholar
• Tsai SL, Sheen IS, Chien RN, Chu CM, Huang HC, Chuang YL, Lee TH, Liao SK, Lin CL, Kuo GC, et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci 2003; 10:120 - 35; http://dx.doi.org/10.1007/BF02256004; PMID: 12566993
   PubMed Web of Science ®Google Scholar
• Tsai SL, Lee TH, Chien RN, Liao SK, Lin CL, Kuo GC, Liaw YF. A method to increase tetramer staining efficiency of CD8+ T cells with MHC-peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment. J Immunol Methods 2004; 285:71 - 87; http://dx.doi.org/10.1016/j.jim.2003.11.005; PMID: 14871536
   PubMed Web of Science ®Google Scholar
• Thammanichanond D, Moneer S, Yotnda P, Aitken C, Earnest-Silveira L, Jackson D, Hellard M, McCluskey J, Torresi J, Bharadwaj M. Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response. Clin Immunol 2008; 128:329 - 39; http://dx.doi.org/10.1016/j.clim.2008.04.002; PMID: 18524682
   PubMed Web of Science ®Google Scholar
• Guo Z, Zhang H, Rao H, Jiang D, Cong X, Feng B, Wang J, Wei L, Chen H. DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response. PLoS One 2012; 7:e38390; http://dx.doi.org/10.1371/journal.pone.0038390; PMID: 22701633
   PubMedGoogle Scholar
• Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008; 9:1; http://dx.doi.org/10.1186/1471-2172-9-1; PMID: 18211710
   PubMed Web of Science ®Google Scholar
• Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363 - 73; PMID: 9531296
   PubMed Web of Science ®Google Scholar
• Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, Scholz S, Santantonio T, Houghton M, Southwood S, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71:6011 - 9; PMID: 9223492
   PubMed Web of Science ®Google Scholar
• Pape GR, Gerlach TJ, Diepolder HM, Grüner N, Jung M, Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999; 6:Suppl 1 36 - 40; http://dx.doi.org/10.1046/j.1365-2893.1999.00006.x; PMID: 10760033
   PubMed Web of Science ®Google Scholar
• Shoukry NH, Sidney J, Sette A, Walker CM. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol 2004; 172:483 - 92; http://dx.doi.org/10.4049/jimmunol.172.1.483; PMID: 14688358
   PubMed Web of Science ®Google Scholar
• Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM, Robbins GK, Szczepiorkowski ZM, Casson DR, Chung RT, et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 2003; 112:831 - 42; http://dx.doi.org/10.1172/JCI200318509; PMID: 12975468
   PubMed Web of Science ®Google Scholar
• Castelli FA, Leleu M, Pouvelle-Moratille S, Farci S, Zarour HM, Andrieu M, Auriault C, Ménez A, Georges B, Maillere B. Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins. Eur J Immunol 2007; 37:1513 - 23; http://dx.doi.org/10.1002/eji.200636783; PMID: 17492804
   PubMed Web of Science ®Google Scholar
• Lamonaca V, Missale G, Urbani S, Pilli M, Boni C, Mori C, Sette A, Massari M, Southwood S, Bertoni R, et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 1999; 30:1088 - 98; http://dx.doi.org/10.1002/hep.510300435; PMID: 10498664
   PubMed Web of Science ®Google Scholar
• Harcourt GC, Lucas M, Sheridan I, Barnes E, Phillips R, Klenerman P. Longitudinal mapping of protective CD4+ T cell responses against HCV: analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes. J Viral Hepat 2004; 11:324 - 31; http://dx.doi.org/10.1111/j.1365-2893.2004.00516.x; PMID: 15230855
   PubMed Web of Science ®Google Scholar
• Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Levine BL, Tobias J, Kwok WW, Chang KM. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol 2008; 82:5043 - 53; http://dx.doi.org/10.1128/JVI.01548-07; PMID: 18337568
   PubMed Web of Science ®Google Scholar
• Eckels DD, Bian T, Gill JC, Sønderstrup G. Epitopes of the NS3 protein of hepatitis C virus: recognition in HLA-DR4 transgenic mice. Immunol Cell Biol 2002; 80:106 - 12; http://dx.doi.org/10.1046/j.1440-1711.2002.01053.x; PMID: 11869368
   PubMed Web of Science ®Google Scholar
• Schulze Zur Wiesch J, Sidney J, Walker B, Sette A. Direct Submission. 2006.
   Google Scholar
• Schulze zur Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE, Wurcel AG, Timm J, Jones AM, Mothe B, et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005; 175:3603 - 13; http://dx.doi.org/10.4049/jimmunol.175.6.3603; PMID: 16148104
   PubMed Web of Science ®Google Scholar
• Wang Y, Keck ZY, Foung SK. Neutralizing antibody response to hepatitis C virus. Viruses 2011; 3:2127 - 45; http://dx.doi.org/10.3390/v3112127; PMID: 22163337
   PubMed Web of Science ®Google Scholar
• He L, De Groot AS, Gutierrez AH, Martin WD, Moise L, Bailey-Kellogg C. Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. BMC Bioinformatics 2014; 15:S1
   Web of Science ®Google Scholar
• De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 2009; 131:189 - 201; http://dx.doi.org/10.1016/j.clim.2009.01.009; PMID: 19269256
   PubMed Web of Science ®Google Scholar
• Duvvuri VR, Duvvuri B, Alice C, Wu GE, Gubbay JB, Wu J. Preexisting CD4+ T-cell immunity in human population to avian influenza H7N9 virus: whole proteome-wide immunoinformatics analyses. PLoS One 2014; 9:e91273; http://dx.doi.org/10.1371/journal.pone.0091273; PMID: 24609014
   PubMed Web of Science ®Google Scholar
• Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother 2014; 15:121 - 30; http://dx.doi.org/10.1517/14656566.2014.857656; PMID: 24289735
   PubMed Web of Science ®Google Scholar
• Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005; 21:379 - 84; http://dx.doi.org/10.1093/bioinformatics/bth485; PMID: 15377502
   PubMed Web of Science ®Google Scholar